These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38170408)

  • 1. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study.
    Doppenberg D; Stoop TF; van Dieren S; Katz MHG; Janssen QP; Nasar N; Prakash LR; Theijse RT; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B; Besselink MG;
    Ann Surg Oncol; 2024 Mar; 31(3):1919-1932. PubMed ID: 38170408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.
    Yousef A; Yousef M; Zeineddine MA; More A; Fanaeian M; Chowdhury S; Knafl M; Edelkamp P; Ito I; Gu Y; Pattalachinti V; Naini ZA; Zeineddine FA; Peterson J; Alfaro K; Foo WC; Jin J; Bhutiani N; Higbie V; Scally CP; Kee B; Kopetz S; Goldstein D; Strach M; Williamson A; Aziz O; Barriuso J; Uppal A; White MG; Helmink B; Fournier KF; Raghav KP; Taggart MW; Overman MJ; Shen JP
    JAMA Netw Open; 2024 Feb; 7(2):e240260. PubMed ID: 38416491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
    Li Z; Zhu H; Pang X; Mao Y; Yi X; Li C; Lei M; Cheng X; Liang L; Wu J; Ding Y; Yang J; Sun Y; Zhang T; You D; Liu Z
    BMC Cancer; 2022 Sep; 22(1):962. PubMed ID: 36076189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study.
    Dekker EN; van Dam JL; Janssen QP; Besselink MG; DeSilva A; Doppenberg D; van Eijck CHJ; Nasar N; O'Reilly EM; Paniccia A; Prakash LR; Tzeng CD; Verkolf EMM; Wei AC; Zureikat AH; Katz MHG; Groot Koerkamp B;
    J Clin Oncol; 2024 Apr; 42(12):1357-1367. PubMed ID: 38315954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
    Janssen QP; van Dam JL; Prakash LR; Doppenberg D; Crane CH; van Eijck CHJ; Ellsworth SG; Jarnagin WR; O'Reilly EM; Paniccia A; Reyngold M; Besselink MG; Katz MHG; Tzeng CD; Zureikat AH; Groot Koerkamp B; Wei AC;
    J Natl Compr Canc Netw; 2022 Jul; 20(7):783-791.e1. PubMed ID: 35830887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
    Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
    Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
    de Haas RJ; Wicherts DA; Flores E; Ducreux M; Lévi F; Paule B; Azoulay D; Castaing D; Lemoine A; Adam R
    Ann Surg Oncol; 2010 Apr; 17(4):1010-23. PubMed ID: 20052553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Zhang Y; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
    Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
    van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
    JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic monitoring of serum CEA and CA19-9 predicts the prognosis of postoperative stage II colon cancer.
    Wang R; Xu B; Sun M; Pang X; Wang X; Zhu J; Lian J; Lu H
    Eur J Surg Oncol; 2023 Dec; 49(12):107138. PubMed ID: 37925830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer.
    Kawamura H; Honda M; Takano Y; Kinuta S; Kamiga T; Saji S; Kono K
    Anticancer Res; 2022 Aug; 42(8):3921-3928. PubMed ID: 35896234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.